OpenAlex
PricingAboutJobs
Log inGet started
Work

A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma

HTML

Year: 2011
Type: article
Study design: Clinical Trial
Source: Oncology
DOI: 10.1159/000327739
Authors: Kristen N. Ganjoo, Lee D. Cranmer, James E. Butrynski, Daniel Rushing, Douglas Adkins, Scott H. Okuno, Gustavo Lorente, Stew Kroll, Virginia K. Langmuir, Sant P. Chawla
Institutions: Stanford Medicine, Stanford University, University of Arizona, Dana-Farber Cancer Institute, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University – Purdue University Indianapolis, Washington University in St. Louis, Mayo Clinic, Threshold Pharmaceuticals (United States), Sarcoma Oncology Center
Language: English

Topic: Sarcoma Diagnosis and Treatment
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: TH-302, hypoxia-activated prodrug, doxorubicin, soft tissue sarcoma, combination chemotherapy, dose-limiting toxicity, maximum tolerated dose, pharmacokinetics, neutropenia, thrombocytopenia, growth factor support, anticancer activity
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2082594665
FWCI: 4.865
Cites: 22
Cited by: 88
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security